SERPINB3 and non-small cell lung carcinoma: The application of docetaxel combined with icotinib in the chemotherapy of advanced NSCLC patients can effectively decrease the expression levels of CEA, SCC and CA125 in serum of patients, reduce adverse reactions, and better improve the quality of life of patients, which is worthy of clinical promotion.